Acceleron Pharma Announces Data Presentations With Luspatercept At The 21st Congress Of The European Hematology Association

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN), a clinical stage biopharmaceutical company focused on the discovery and development of novel therapeutic candidates that engage the body’s ability to rebuild and repair its own cells and tissues, today announced that data from four abstracts with the therapeutic candidate luspatercept, were accepted for presentation at the 21st Congress of the European Hematology Association (EHA). The meeting will be held in Copenhagen, Denmark from June 9-12, 2016.